• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?剂量调整后的EPOCH-R方案在儿童原发性纵隔B细胞淋巴瘤患者中比在成人患者中疗效更差吗？
J Clin Oncol. 2022 Jun 20;40(18):2063-2064. doi: 10.1200/JCO.21.02593. Epub 2022 Apr 4.
2
Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.剂量调整的EPOCH-利妥昔单抗或强化B-NHL疗法用于儿童原发性纵隔大B细胞淋巴瘤。
Haematologica. 2021 Dec 1;106(12):3232-3235. doi: 10.3324/haematol.2021.278971.
3
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.剂量调整的EPOCH-R方案（依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素和利妥昔单抗）用于治疗未经治疗的伴有MYC重排的侵袭性弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、单臂2期研究。
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
4
Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.剂量调整的EPOCH-R方案用于新诊断的伴有MYC重排的弥漫性大B细胞淋巴瘤患者。
J Clin Exp Hematop. 2020 Jun 20;60(2):60-61. doi: 10.3960/jslrt.20004. Epub 2020 May 13.
5
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.剂量调整的EPOCH联合利妥昔单抗（DA-EPOCH-R）方案用于初治预后不良的大B细胞淋巴瘤患者的长期随访。西班牙PETHEMA研究组开展的一项II期研究。
Br J Haematol. 2015 Apr;169(2):188-98. doi: 10.1111/bjh.13273. Epub 2014 Dec 18.
6
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松（R-CHOP）方案与剂量调整的利妥昔单抗联合依托泊苷、泼尼松、长春新碱、阿霉素和环磷酰胺（R-EPOCH）方案用于原发性纵隔B细胞淋巴瘤一线治疗的多中心分析
Br J Haematol. 2018 Feb;180(4):534-544. doi: 10.1111/bjh.15051. Epub 2017 Dec 19.
7
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.维奈托克联合剂量调整的 EPOCH-R 方案作为侵袭性 B 细胞淋巴瘤患者的初始治疗：一项单臂、多中心、1 期研究。
Lancet Haematol. 2021 Nov;8(11):e818-e827. doi: 10.1016/S2352-3026(21)00273-8. Epub 2021 Oct 8.
8
Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman.一例跨性别女性原发性纵隔大 B 细胞淋巴瘤患者接受 DA-EPOCH-R 方案治疗获得成功。
Intern Med. 2024 Jul 1;63(13):1923-1927. doi: 10.2169/internalmedicine.2701-23. Epub 2023 Nov 20.
9
DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?DA-R-EPOCH 与 R-CHOP 方案在弥漫大 B 细胞淋巴瘤中的比较：我们该如何选择？
Clin Adv Hematol Oncol. 2021 Nov;19(11):698-709.
10
Venetoclax Boosts Benefits of R-EPOCH in Aggressive B-Cell Lymphomas.维奈托克增强 R-EPOCH 方案在侵袭性 B 细胞淋巴瘤中的获益。
Oncologist. 2020 Jul;25 Suppl 1(Suppl 1):S14-S15. doi: 10.1634/theoncologist.2020-0569. Epub 2020 Jun 26.

本文引用的文献

1
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.依托泊苷、多柔比星和环磷酰胺联合长春新碱和泼尼松加利妥昔单抗治疗儿童和青少年原发性纵隔 B 细胞淋巴瘤：一项多中心 II 期试验。
J Clin Oncol. 2021 Nov 20;39(33):3716-3724. doi: 10.1200/JCO.21.00920. Epub 2021 Sep 27.
2
Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.剂量调整的EPOCH-利妥昔单抗或强化B-NHL疗法用于儿童原发性纵隔大B细胞淋巴瘤。
Haematologica. 2021 Dec 1;106(12):3232-3235. doi: 10.3324/haematol.2021.278971.
3
Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring.多柔比星致心肌毒性的研究进展：分子机制、预防策略及早期监测。
Mol Pharmacol. 2019 Aug;96(2):219-232. doi: 10.1124/mol.119.115725. Epub 2019 Jun 4.
4
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.剂量调整 EPOCH-R 与 R-CHOP 作为弥漫性大 B 细胞淋巴瘤一线治疗的比较：III 期联合组试验联盟/CALGB 50303 的临床结果。
J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.
5
A prospective study of mediastinal gray-zone lymphoma.纵隔灰色地带淋巴瘤的前瞻性研究。
Blood. 2014 Sep 4;124(10):1563-9. doi: 10.1182/blood-2014-03-564906. Epub 2014 Jul 14.
6
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.剂量调整的 EPOCH-利妥昔单抗治疗原发性纵隔 B 细胞淋巴瘤。
N Engl J Med. 2013 Apr 11;368(15):1408-16. doi: 10.1056/NEJMoa1214561.
7
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.接受两疗程COPAD化疗的儿童和青少年切除性局限性B细胞非霍奇金淋巴瘤患者生存率极佳：FAB/LMB 96国际研究结果
Br J Haematol. 2008 Jun;141(6):840-7. doi: 10.1111/j.1365-2141.2008.07144.x. Epub 2008 Mar 26.
8
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.含阿霉素方案在复发和耐药淋巴瘤中的作用：EPOCH的8年随访研究
J Clin Oncol. 2000 Nov 1;18(21):3633-42. doi: 10.1200/JCO.2000.18.21.3633.
9
CNS involvement in primary mediastinal large B-cell lymphoma.中枢神经系统受累于原发性纵隔大B细胞淋巴瘤。
J Clin Oncol. 1999 Aug;17(8):2479-85. doi: 10.1200/JCO.1999.17.8.2479.
10
The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.
J Clin Oncol. 1991 Feb;9(2):339-47. doi: 10.1200/JCO.1991.9.2.339.

Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?

作者信息

Lakhotia Rahul, Melani Christopher, Roschewski Mark, Wilson Wyndham H

机构信息

Rahul Lakhotia, MBBS, Christopher Melani, MD, Mark Roschewski, MD, and Wyndham H. Wilson, MD, PhD, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

出版信息

J Clin Oncol. 2022 Jun 20;40(18):2063-2064. doi: 10.1200/JCO.21.02593. Epub 2022 Apr 4.

DOI:10.1200/JCO.21.02593
PMID:35377729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9197344/
Abstract
摘要